Abstract :Background: The CYP2C19*17 allele has been shown to be related to faster Pantoprazole
metabolism, whereas the *2 and *3 alleles are related to poor metabolism. We aimed to investigate
the effect of CYP2C19 polymorphisms on treatment of gastro-esophageal reflux disease.
Materials and Methods: Patients admitted to the Endoscopy unit and diagnosed with grade A or
B esophagitis were included in the study. Patients were enrolled in two groups: Group 1 (N: 50)
consisted of patients taking 40 mg Pantoprazole, and Group 2 (N: 41) those taking 80 mg per day.
After 8 weeks of treatment, a second endoscopic procedure was performed to evaluate healing of
the esophagitis. In addition, CYP2C19 genotyping for *2, *3 and *17 was performed for all of the
patients.
Results: The healing rates of esophagitis were 82% and 80.5% in Groups 1 and 2, respectively. All of
the patients with the *2*2 polymorphism were cured, in contrast only 66.7% of those with the *17*17
polymorphism healed.
Conclusion: In this preliminary study, the healing rates of esophagitis were comparable to results
of reported studies in the literature. Being slow metabolizer may be a favorable effect on GERD
treatment outcome.